Vimarsana
Biggest News Aggregation in the World

Oncology Intelligence News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncology Intelligence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncology Intelligence Today - Breaking & Trending Today

Imagene Advances LungOI Commercialization With New Payment Code and Pricing, Complementing Its Prior CLIA Certified US Lab - Vimarsana News

Imagene Advances LungOI Commercialization With New Payment Code and Pricing, Complementing Its Prior CLIA Certified US Lab

LungOI Is Among The First AI-based Tests To Receive a Medicare Payment Rate.MIAMI, FL / ACCESSWIRE / May 28, 2024 / Imagene, a pioneer in AI-based precision oncology, is pleased to announce the culmination

Certis Oncology Closes $10M Series C Funding - Vimarsana News

Certis Oncology Closes $10M Series C Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Certis Oncology Named 'Overall Immunology Company of the Year' in 2023 BioTech Breakthrough Awards - Vimarsana News

Certis Oncology Named 'Overall Immunology Company of the Year' in 2023 BioTech Breakthrough Awards

SAN DIEGO--(BUSINESS WIRE)--#CertaintySavesLives--Certis Oncology Solutions (Certis), a translational science and precision oncology company, today announced it has been selected as "Overall Immunology Company of the Year" in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a l...

AI in Cancer Research: Optimizing Biomarker Discovery, Model Selection, and Preclinical Decision-Making, Upcoming Webinar, Hosted by Xtalks - Vimarsana News

AI in Cancer Research: Optimizing Biomarker Discovery, Model Selection, and Preclinical Decision-Making, Upcoming Webinar, Hosted by Xtalks

Toronto, ON (PRWEB) April 25, 2023 -- AI-enabled technologies are revolutionizing the drug development process, from target identification and lead

Source: prweb.com